123 related articles for article (PubMed ID: 9707020)
1. Recombinant human erythropoietin (rh-Epo) administration to normal child bone marrow donors.
Martínez AM; Sastre A; Muñoz A; Badell I; Maldonado MS; Cubells J
Bone Marrow Transplant; 1998 Jul; 22(2):137-8. PubMed ID: 9707020
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human erythropoietin (rh-Epo) administration to normal marrow donors.
York A; Clift RA; Sanders JE; Buckner CD
Bone Marrow Transplant; 1992 Nov; 10(5):415-7. PubMed ID: 1464002
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group.
Biggs JC; Atkinson KA; Booker V; Concannon A; Dart GW; Dodds A; Downs K; Szer J; Turner J; Worthington R
Bone Marrow Transplant; 1995 Jan; 15(1):129-34. PubMed ID: 7742745
[TBL] [Abstract][Full Text] [Related]
5. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats.
Kato M; Kamiyama H; Okazaki A; Kumaki K; Kato Y; Sugiyama Y
J Pharmacol Exp Ther; 1997 Nov; 283(2):520-7. PubMed ID: 9353365
[TBL] [Abstract][Full Text] [Related]
6. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise.
Russell G; Gore CJ; Ashenden MJ; Parisotto R; Hahn AG
Eur J Appl Physiol; 2002 Mar; 86(5):442-9. PubMed ID: 11882931
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of erythropoietin in genetically anemic mice.
Kato M; Miura K; Kamiyama H; Okazaki A; Kumaki K; Kato Y; Sugiyama Y
Drug Metab Dispos; 1998 Feb; 26(2):126-31. PubMed ID: 9456298
[TBL] [Abstract][Full Text] [Related]
8. In vivo effects of recombinant human erythropoietin on bone marrow hematopoiesis in patients with chronic renal failure.
Biljanović-Paunović L; Djukanović L; Lezaić V; Stojanović N; Marisavljević D; Pavlović-Kentera V
Eur J Med Res; 1998 Dec; 3(12):564-70. PubMed ID: 9889177
[TBL] [Abstract][Full Text] [Related]
9. Autologous blood transfusion for pediatric bone marrow donors.
Chan KW; Herd SL; Stanley CE; Wadsworth LD
Bone Marrow Transplant; 1992 May; 9(5):365-7. PubMed ID: 1617320
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness to recombinant human erythropoietin (rh-Epo) of marrow erythroid progenitors (CFU-E and BFU-E) from B-chronic lymphocytic leukemia (B-CLL).
Tsatalas C; Chalkia P; Tsantali C; Kakoulidis I; Garyfallos A; Klonizakis I; Panayiotopoulos S
J Exp Clin Cancer Res; 1997 Jun; 16(2):163-70. PubMed ID: 9261742
[TBL] [Abstract][Full Text] [Related]
11. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of neonatal anemia with recombinant human erythropoietin: a cost-benefit analysis].
Schefels J; Merz U; Hörnchen H
Z Geburtshilfe Neonatol; 1999 Dec; 203 Suppl 2():1-5. PubMed ID: 10612190
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin and prematurity--where do we stand?
Carbonell-Estrany X; Figueras-Aloy J; Alvarez E
J Perinat Med; 2005; 33(4):277-86. PubMed ID: 16207112
[TBL] [Abstract][Full Text] [Related]
15. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
17. Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors.
Ordemann R; Hölig K; Wagner K; Rautenberg U; Bornhäuser M; Kroschinsky F; Schäfer J; Schuler U; Ehninger G
Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S25-8. PubMed ID: 9712488
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
20. The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants.
Türker G; Sarper N; Gökalp AS; Usluer H
Am J Perinatol; 2005 Nov; 22(8):449-55. PubMed ID: 16283605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
